SecBot SecBot
6-K ·Filed May 15, 2026

BNTX

BioNTech SE
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001776985-26-000035
Notable filing: 6-K
Actionable Insight • Neutral

The AGM is largely a routine governance event with no new material financial disclosures beyond what was reported in the Q1 2026 6-K on May 5. The $1.0B buyback is a modest capital return signal but does not offset the declining revenue trajectory. Monitor upcoming oncology pipeline catalysts (pumitamig data readouts) as the primary value driver.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$88.85
T+0 close · May 15, 2026 · via day close
Latest settled
+4.38%
T+60 · $92.74
Vs SPY
−0.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $88.85entry
  2. T+1 · 6mo ago −1.19%α −0.54% · $87.79
  3. T+5 · 6mo ago +3.83%α +2.21% · $92.25
  4. T+20 · 5mo ago +0.73%α −0.85% · $89.50
  5. T+60 · 3mo ago +4.38%α −0.47% · $92.74

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech held its 2026 Annual General Meeting, where all agenda items were approved by shareholders, including expanding the Supervisory Board from six to eight members and electing two new members. The AGM presentation reaffirmed FY2026 revenue guidance of $2.0-2.3 billion (non-IFRS) and announced a $1.0 billion share repurchase program over the next twelve months, while highlighting the ongoing transition from COVID-19 vaccine revenues toward a late-stage oncology pipeline.

Key Facts

  • Shareholders approved expanding the Supervisory Board from six to eight members and elected Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert as new members.
  • FY2026 non-IFRS revenue guidance reaffirmed at $2.0-2.3 billion, down from FY2025 IFRS revenue of $2.87 billion.
  • Q1 2026 unaudited IFRS revenues were $118 million, down from $183 million in Q1 2025.
  • Q1 2026 IFRS net loss was $532 million ($2.10 per share), compared to a net loss of $416 million ($1.73 per share) in Q1 2025.
  • Cash and cash equivalents plus security investments totaled $16.8 billion as of March 31, 2026.
  • Announced a share repurchase program of up to $1.0 billion over the next twelve months.
  • Manufacturing footprint consolidation expected to achieve approximately $500 million in recurring annual savings by 2029.
  • BMS partnership for pumitamig includes $3.5 billion upfront and non-contingent payments plus $7.6 billion in milestone payments.

Financial Impact

FY2026 revenue guidance of $2.0-2.3 billion (non-IFRS) vs FY2025 IFRS revenue of $2.87 billion; Q1 2026 revenue $118M vs $183M YoY; Q1 2026 net loss $532M vs $416M YoY; $16.8B cash position; $1.0B buyback authorized.

revenuenet incomecash positionshare repurchase

Risk Factors

  • COVID-19 vaccine revenue continues to decline faster than oncology pipeline can offset.
  • FY2026 revenue guidance of $2.0-2.3 billion implies a 20-30% decline from FY2025.
  • Operating losses are widening ($677M in Q1 2026 vs $534M in Q1 2025) as R&D spending remains elevated.
  • Competitive dynamics in the US COVID-19 vaccine market and transition away from multi-year European contracts create revenue uncertainty.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000035
Document: form6-k2026agm15may2026.htm0001776985-26-000035
Document: a99120260515_bntxxagmxenxf.htm0001776985-26-000035
Document: a993votingresults.htm0001776985-26-000035
Document: 0001776985-26-000035-index-headers.html0001776985-26-000035
Document: 0001776985-26-000035-index.html0001776985-26-000035
Document: 0001776985-26-000035.txt0001776985-26-000035

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (14h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026